2004
Combining norepinephrine and serotonin reuptake inhibition mechanisms for treatment of depression: a double-blind, randomized study
Nelson JC, Mazure CM, Jatlow PI, Bowers MB, Price LH. Combining norepinephrine and serotonin reuptake inhibition mechanisms for treatment of depression: a double-blind, randomized study. Biological Psychiatry 2004, 55: 296-300. PMID: 14744472, DOI: 10.1016/j.biopsych.2003.08.007.Peer-Reviewed Original ResearchMeSH KeywordsAdrenergic Uptake InhibitorsAdultAntidepressive Agents, Second-GenerationAntidepressive Agents, TricyclicChromatography, High Pressure LiquidDepressive DisorderDesipramineDouble-Blind MethodDrug Therapy, CombinationFemaleFluoxetineHumansMaleMiddle AgedNorepinephrinePsychiatric Status Rating ScalesSelective Serotonin Reuptake InhibitorsSerotoninTreatment OutcomeConceptsMontgomery-Asberg Depression Rating ScaleHamilton Depression Rating Scale scoresDepression Rating Scale scoresNonpsychotic unipolar major depressionPatient withdrew consentTreatment-resistant patientsWeeks of hospitalizationWeeks of treatmentCombination of fluoxetineOnset of actionAdequate plasma levelsDouble-blind conditionsDepression Rating ScaleTreatment of depressionRating Scale scoresUnipolar major depressionDrug plasma concentrationsDMI doseWithdrew consentAntidepressant medicationRandomized studyReuptake inhibitionSerotonergic agentsPlasma levelsMajor depression
2001
Antidepressant-associated mania and psychosis resulting in psychiatric admissions.
Preda A, MacLean RW, Mazure CM, Bowers MB. Antidepressant-associated mania and psychosis resulting in psychiatric admissions. The Journal Of Clinical Psychiatry 2001, 62: 30-3. PMID: 11235925, DOI: 10.4088/jcp.v62n0107.Peer-Reviewed Original ResearchConceptsSelective serotonin reuptake inhibitorsGeneral hospital psychiatric unitAntidepressant-associated maniaNewer atypical agentsSide effect profileSerotonin reuptake inhibitorsHospital psychiatric unitRate of admissionAdverse behavioral effectsAntidepressant useReuptake inhibitorsEffect profileAtypical agentsPsychiatric admissionsAntidepressant drugsPsychiatric unitBehavioral effectsAdverse behavioral reactionsAdmissionSignificant increasePsychosisManiaDrugsTolerabilityAntidepressants
1989
Clinical Implications of the Pharmacokinetics of Tricyclic Antidepressants
Nelson JC, Mazure C, Jatlow PI. Clinical Implications of the Pharmacokinetics of Tricyclic Antidepressants. Psychopharmacology Series 1989, 7: 219-227. PMID: 2687860, DOI: 10.1007/978-3-642-74430-3_24.Peer-Reviewed Original Research
1988
Antidepressant activity of 2‐hydroxydesipramine
Nelson J, Mazure C, Jatlow P. Antidepressant activity of 2‐hydroxydesipramine. Clinical Pharmacology & Therapeutics 1988, 44: 283-288. PMID: 3416551, DOI: 10.1038/clpt.1988.151.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntidepressive Agents, TricyclicDepressive DisorderDesipramineFemaleHumansMaleMiddle AgedProspective StudiesTime FactorsConceptsPlasma levelsOH-DMIAntidepressant activityDSM-III major depressionDMI levelsSteady-state plasma levelsWeeks of hospitalizationDrug plasma levelsFixed-dose protocolTotal drug levelsMajor depressionDrug levelsParent drugMeasure of responseTrialsResponsePrior studiesHospitalizationLevelsMedicationsPatientsInpatientsNonpsychoticDoseWeeks